Bibliography
- Small DM. Cellular mechanisms for lipid deposition in atherosclerosis (first of two parts). N Engl J Med 1977;297(16):873-7
- Shah PK. Inflammation and plaque vulnerability. Cardiovasc Drugs Ther 2009;23(1):31-40
- Newby DE. Triggering of acute myocardial infarction: beyond the vulnerable plaque. Heart 2010;96(15):1247-51
- Roubille F, Kritikou EA, Roubille C, Tardif JC. Emerging Anti-Inflammatory Therapies For Atherosclerosis. Curr Pharm Des 2013; [Epub ahead of print]
- Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010;74(2):213-20
- Roubille F, Tardif JC. Anti-inflammatory drugs and the heart. Antiinflamm Antiallergy Agents Med Chem 2013;12(1):2
- Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195-207
- Moubayed SP, Heinonen TM, Tardif JC. Anti-inflammatory drugs and atherosclerosis. Curr Opin Lipidol 2007;18(6):638-44
- Tardif JC, McMurray JJ, Klug E, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371(9626):1761-8
- Ridker PM. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep 2013;15(1):295
- Berman JP, Farkouh ME, Rosenson RS. Emerging anti-inflammatory drugs for atherosclerosis. Expert Opin Emerg Drugs 2013;18(2):193-205
- Farmakis D, Andreadou I, Aessopos A. High-sensitivity troponin assays: ready for prime-time use as surrogates of subclinical myocardial injury? J Am Coll Cardiol 2012;60(2):166; author reply 68
- Tardif JC, Heinonen T, Orloff D, Libby P. Vascular biomarkers and surrogates in cardiovascular disease. Circulation 2006;113(25):2936-42
- Puri R, Worthley MI, Nicholls SJ. Intravascular imaging of vulnerable coronary plaque: current and future concepts. Nat Rev Cardiol 2011;8(3):131-9
- Tardif JC, L'Allier P L, Ibrahim R, et al. Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging 2010;3(3):298-307
- Tardif JC, Tanguay JF, Wright SS, et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST elevation myocardial infarction Results of the SELECT-ACS Trial. J Am Coll Cardiol 2013;61(20):2048-55